Polymorphisms of ACMSD-TMEM163, MCCC1, and BCKDK-STX1B Are Not Associated with Parkinson’s Disease in Taiwan
Table 5
Comparisons of minor allelic and genotypic frequencies of single nucleotide polymorphisms (SNPs) between early-onset Parkinson’s disease (EOPD) and late-onset Parkinson's disease (LOPD) patients and the controls.
Minor allele of each SNP
PD (N, %)
Controls (N, %)
OR (95% CI)
value
EOPD (allele)
178
250
ACMSD-TMEM163 rs6430538, C
3 (1.7)
2 (0.8)
2.13 (0.35∼12.85)
0.40
TT
86 (96.6)
123 (98.4)
TC
3 (3.3)
2 (1.6)
2.15 (0.35∼13.11)
0.40
CC
0
0
MCCC1 rs12637471, G
89 (50.0)
115 (46.0)
1.17 (0.80∼1.73)
0.41
AA
27 (30.3)
36 (28.8)
GA
35 (39.3)
63 (50.4)
0.74 (0.39∼1.42)
0.36
GG
27 (30.3)
26 (20.8)
1.39 (0.66∼2.89)
0.38
BCKDK-STX1B rs14235, G
19 (10.7)
24 (9.6)
1.13 (0.60∼2.12)
0.72
AA
70 (78.7)
102 (81.6)
GA
19 (21.3)
22 (17.6)
1.26 (0.63∼2.50)
0.51
GG
0
1 (0.8)
LOPD (allele)
1020
946
ACMSD-TMEM163 rs6430538, C
13 (1.3)
18 (1.9)
0.67 (0.32∼1.37)
0.27
TT
498 (97.6)
455 (96.2)
TC
11 (2.2)
18 (3.8)
0.56 (0.26∼1.20)
0.13
CC
1 (0.2)
0
MCCC1 rs12637471, G
422 (41.4)
402 (42.5)
0.96 (0.80∼1.14)
0.61
AA
170 (33.3)
156 (33.0)
GA
258 (50.6)
232 (49.0)
1.02 (0.77∼1.35)
0.89
GG
82 (16.1)
85 (18.0)
0.89 (0.61∼1.29)
0.52
BCKDK-STX1B rs14235, G
100 (9.8)
91 (9.6)
1.02 (0.76∼1.38)
0.89
AA
413 (81.0)
386 (81.6)
GA
94 (18.4)
83 (17.5)
1.06 (0.76∼1.47)
0.73
GG
3 (0.6)
4 (0.8)
0.70 (0.16∼3.15)
0.64
SNP: single nucleotide polymorphism; OR: odds ratio; CI: confidence interval.
